Roche and Foundation Medicine’s New Blood Test Method Can Help Customize Cancer Immunotherapy

Roche and Foundation Medicine’s new blood test method can help customize cancer immunotherapy

Roche- a multinational healthcare company based in Switzerland together with Foundation Medicine recently invented a new blood test method that can precisely measure the amount of mutations within a cancer tumor. This test can potentially help in predicting which patients will be able to respond proficiently to some types of immunotherapies. The outcome of the test was revealed on September 8, 2017. Initial data derived from the test conducted by Roche that focused on determining the mutational burden of the TMB or tumor was disclosed on Friday- 8th September, at ESMO (the European Society for Medical Oncology) in Madrid. Immunotherapies like Opdivo by Bristol-Myers Squibb and Keytruda by Roche’s Tecentriq have enabled people to freshly hope for the best and combat deadly cancers. However, these immunotherapies work only in a small number of patients.

Immunotherapies such as Roche’s Tecentriq, Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo have offered fresh hope to people with deadly cancers, but they only work in a fraction of patients suffering from cancer. Given the fact that the immunotherapies are extremely costly and have some serious side effects, and with many British regulators dubbing Tecentriq as highly expensive, doctors are looking for advanced ways to recognize which patients will be able to benefit the most with the help of such treatments and tests. According to certain evidences, the cancer tumor having more mutations is easily able to respond to immunotherapy, the company mentioned.

Roche also added that it is hoping that the new test will help them to improve measuring of TMB, especially at the time when invasive biopsies are not recommended and feasible. Roche says that there no such blood tests are introduced to the market till date. Chief medical officer of Roche, Sandra Horning mentioned that, “Biomarkers are not only going to enhance our understanding of immune biology but are also going to eventually help match our combinations and therapies for the patients most likely to get treated and benefited with the therapy.”

You may be interested

Sustainable Seafood Market Trends, Working Capital, and opportunities Analysis 2026
Business
Business

Sustainable Seafood Market Trends, Working Capital, and opportunities Analysis 2026

Mohit Joshi - December 17, 2018

Sustainable Seafood Market Report 2018 look into the study is an exceptionally tenacious examination on aggressive scene investigation, prime makers, showcasing procedures examination, Market Effect Factor Analysis…

Cardiac Monitoring Devices Market 2018 Expected Vast Growth By 2026 Including Freelancers, Intake, Trials & Forecast By Application, Technologies
Business
Business

Cardiac Monitoring Devices Market 2018 Expected Vast Growth By 2026 Including Freelancers, Intake, Trials & Forecast By Application, Technologies

Mohit Joshi - December 17, 2018

Cardiac Monitoring Devices Market Report 2018 look into the study is an exceptionally tenacious examination on aggressive scene investigation, prime makers, showcasing procedures examination, Market Effect Factor…

Molecular Sieve Catalyst Market Value Share, Analysis and Segments 2015-2025
Business
Business

Molecular Sieve Catalyst Market Value Share, Analysis and Segments 2015-2025

Rachel Stinson - December 17, 2018

Molecular Sieve Catalyst Market Report 2018 look into the study is an exceptionally tenacious examination on aggressive scene investigation, prime makers, showcasing procedures examination, Market Effect Factor…

Most from this category